NT219

PreclinicalSmall molecule

NT219 is one of 71 small molecule programs targeting Head and Neck Squamous Cell Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Head and Neck Squamous Cell CarcinomaActive, not recruiting

Head and Neck CancerActive, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 1/Phase 2

Active, not recruiting

Head and Neck CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

281 competitors in Head and Neck Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

36 2

Erbitux

IImclone

Phase 3

26 3

Beyfortus

BeiGene

Phase 3

7 4

Imfinzi

AstraZeneca

Phase 3

5 5

Taxotere

AAvyxa

Phase 3

16 6

Lenvima

Eisai

Phase 3

4 7

Ibrance

Pfizer

Phase 3

4 8

Imjudo

AstraZeneca

Phase 3

1 9

Tuoyi

CCoherus Oncology, Inc.

Phase 3

6 10

Gilotrif

Boehringer Ingelheim

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

PreclinicalActive, not recruiting

Head and Neck Cancer

NCT06919666

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer

Completed·TTyrNovo Ltd.·Phase 1/2·NCT04474470·52 enrolled

Head and Neck Cancer1 trial

Phase Ib/II Study of NT219 in Combination With Pembrolizumab or Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Active, not recruiting·UUniversity of Colorado, Denver·Preclinical·NCT06919666·29 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for NT219. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NT219 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NT219. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Colorado, Denver company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Colorado, Denver

NT219

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Advanced Solid Tumors1 trial

Head and Neck Cancer1 trial

References

Drug Info

Quick Facts

Related News